Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Cancer immunity cycle
- Adoptive T cell therapy (ACT) approaches
- Optimal ACT needs
- CAR-T development
- CAR-T in the clinic
- CAR-T for solid tumour
- CAR-T therapy for osteosarcoma
- CAR vs. TCR therapy
- TCR vs. CAR
- TCR therapy for solid tumour
- TCR affinity
- TCR therapy to date
- Source of therapeutic TCR
- TCR therapy against colon cancer
- Tumour-immune cell interactions in MSI+ cancer
- Radium-1 TCR recognising frameshift peptide
- Transient TCR/CAR expression
- Transient expression of Radium-1 TCR
- B-cell lymphoma CAR (1)
- B-cell lymphoma CAR (2)
- Is TCR therapy safe?
- CRISPR-engineered T cells
- Safety of CRISPR-engineered T cells
- T cells resistant to the TME
- Main focus on CD8 T cells
- Why using CD4 T cells?
- MHC class II antigen presentation
- Allogeneic source of cells
- Universal killer cells (1)
- Universal killer cells (2)
- A universal solution
- Acknowledgements
Topics Covered
- Cancer immunity and adoptive cell therapy
- CAR-T and TCR-based therapy treating solid tumours
- Examples in osteosarcoma and colon cancer
- Transient CAR or TCR expression for safety evaluation
- Factors affecting in vivo efficacy and T-cell persistence
- A universal allogeneic therapeutic product
Links
Series:
- The Immune System - Key Concepts and Questions
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Inderberg, E.M. (2021, October 28). Latest advances in the development of CAR & TCR T-cell treatments for solid tumours [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/ZZWE5039.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Inderberg is a co-inventorship on several patents for TCR and CAR-based cellular therapy, as well as co-founder of Zelluna Immunotherapy AS.
Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
Published on October 28, 2021
28 min
Other Talks in the Series: The Immune System - Key Concepts and Questions
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Else Marit Inderberg.
I am a Principal Investigator at
the University Hospital at the Norwegian Radium Hospital site in Oslo, Norway.
I will give a presentation on the latest advances in
the development of CAR and TCR T-cell treatments for solid tumors.
0:21
This is the cancer immunity cycle,
which explains briefly how the immune system is
activated by cancer cells and can react against them.
Some cancer cells will die and release cancer proteins or antigens, as seen in stage one.
These antigens are then taken up by
dendritic cells and other antigen-presenting cells will
migrate to lymph nodes to present the cancer antigens on MHC molecules to T-cells.
Cancer-specific T-cells will become activated and
proliferate before they go into the bloodstream to look for tumor cells.
Tumors become infiltrated by T-cells,
recognizing the same cancer antigens and cancer cells are killed to
release new antigens and the cycle is repeated with a broader immune response.
1:08
Adoptive cell therapy using ex vivo expanded tumor-infiltrating lymphocytes or Tils,
has been the most effective treatment for patients
with metastatic melanoma with a response rate
of over 50 percent and durable responses in 20 percent of patients.
However, in other cancers,
Tils are not easy to culture and different strategies
engineering cancer-specific lymphocytes have been developed.
Patient T-cells from the blood can be genetically modified to express
chimeric antigen receptors antigen T-cell receptors, TCRs.
These are then expanded ex vivo before that reinfused back into the patient.
Hide